Filter posts

JAMA Study Misses the Mark on Cancer R&D Costs & Profitability

Yesterday, JAMA Internal Medicine published a new paper purporting to estimate the R&D expense associated …

2017 BIO Patient Advocacy Pavilion: Bringing Patient Centricity to the Forefront

The role of patient advocacy organizations in the life cycle of drug development has gone …

Best Practices for Communication Between FDA and IND Sponsors During Drug Development

The FDA recently released an online course to provide insights to drug sponsors on communicating …

2016 Snapshot: BIO’s Top Five Health Blogs

There was no shortage of health hot topics this year, but as 2016 comes to …

BIO Releases Largest Study Ever on Clinical Development Success Rates

On Wednesday, BIO released the largest ever study of clinical development success rates. The study, conducted in …

ICYMI: John Lechleiter: An Empty Obama-Clinton-Sanders Plan on Drug Costs

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO …

Integrating the Patient Voice: Recap of the 2016 BIO CEO & Investor Conference

The 2016 BIO CEO & Investor Conference isn’t just for biotech companies and the investment …

Setting the Record Straight on Innovation and Drug Development

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, …

Expanding the Role of Patients in Drug Development

Working alongside scientists, universities, and biotech companies, patients and patient organizations have the ability to …

Time: How to Breathe New Life Into America's Health-Care System

Last week, Rep. Fred Upton (R-MI) published an op-ed – How to Breathe New Life Into America’s …